iobitridol (Xenetix) Report issue

Small molecule Imaging Experimental
AACT ChEMBL DrugBank Drug Central KEGG MeSH PubChem

Active Ingredient History

NOW
  • Now
Iobitridol is a pharmaceutical drug used as an iodine-based radiocontrast agent in X-ray imaging. It is injected into blood vessels, joints, or body cavities such as the uterus, and filtered out by the kidneys. Its most common adverse effect is nausea. Severe allergic reactions are rare.   Wikipedia

Chemistry

  • SMILES: CN(CC(O)CO)C(=O)c1c(I)c(NC(=O)C(CO)CO)c(I)c(C(=O)N(C)CC(O)CO)c1I
  • InChIKey: YLPBXIKWXNRACS-UHFFFAOYSA-N
  • Mol. Mass: 835.17
  • ALogP: -1.11
  • ChEMBL Molecule:
    iobitridol  
More Chemistry

Pharmacology

  • Mechanism of Action:
  • Multi-specific: Missing data
  • Black Box: No
  • Availability: Missing data
  • Delivery Methods: Missing data
  • Pro Drug: No

Alternative names

5-(3-hydroxy-2-hydroxymethylpropionamido)-n,n'-dimethyl-n,n'-bis(2,3-dihydroxypropyl)-2,4,6-triiodoisophthalamide | iobitridol | xenetix

Organizations (6)

Research & Development (6)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Marketing (0)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Indications (6)

Approved Indications (1)


 

Radiography

Experimental Indications - Clinical Trial Phases 1-4 (5)


 

Carcinoma, Hepatocellular (Phase 4)

Coronary Artery Disease (Phase 4)

Diabetes Mellitus, Type 2 (Phase 4)

Diagnostic Imaging (Phase 4)

Kidney Diseases (Early Phase 1)

Overview

  • Highest Phase: Phase 4
  • # of Trials: 7
  • # of Trial Organizations: 6

Trials by Phase

Trial Phase Start Date Organizations Indications

Feedback

Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue